Application | Comment | Organism |
---|---|---|
drug development | FAAH is an attractive target for treating pain | Mus musculus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester | i.e. URB597, attenuates the development of lipopolysaccharide-induced paw edema and reverses lipopolysaccharide-induced hyperalgesia through the respective CB2 and CB1 mechanisms of action. The inhibition is not affected by capsazepine, a transient receptor potential vanilloid type 1 antagonist | Mus musculus |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
anandamide + H2O | Mus musculus | i.e. N-arachidonoylethanolamine | arachidonic acid + ethanolamine | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
male C57BL/6J mice | - |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
neuron | - |
Mus musculus | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
anandamide + H2O | i.e. N-arachidonoylethanolamine | Mus musculus | arachidonic acid + ethanolamine | - |
? |
Synonyms | Comment | Organism |
---|---|---|
FAAH | - |
Mus musculus |
General Information | Comment | Organism |
---|---|---|
physiological function | FAAH is the chief catabolic enzyme regulating the endogenous cannabinoid N-arachidonoylethanolamine, i.e. anandamide | Mus musculus |